Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway

Oncology Reports

Volumn 34, Issue 2, 2015, Pages 663-672

  Lin, Lele ^a   Jiang, Hongpeng ^a   Huang, Mingkui ^a   Hou, Xu ^a   Sun, Xuepu ^a   Jiang, Xian ^a   Dong, Xuesong ^a   Sun, Xueying ^a,b   Zhou, Baoguo ^a   Qiao, Haiquan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CD44; Gastric cancer; Histone deacetylase 1; Metastases; miR 34a

Indexed keywords

GELATINASE A; HERMES ANTIGEN; HISTONE DEACETYLASE 1; LIM KINASE 1; MESSENGER RNA; MICRORNA 34A; PROTEIN BCL 2; PROTEIN P53; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; CD44 PROTEIN, HUMAN; HDAC1 PROTEIN, HUMAN; MICRORNA; MIRN34 MICRORNA, HUMAN;

ACTIN FILAMENT; ARTICLE; CELL ADHESION; CELL INVASION; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; ENZYME ACTIVATION; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSEUDOPODIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; CELL MOTION; DEFICIENCY; DNA MICROARRAY; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

ANTIGENS, CD44; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HUMANS; MICRORNAS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84931376701     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4010     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
3. Venugopal B and Evans TR: Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18: 1658-1671, 2011.
4. Dovey OM, Foster CT and Cowley SM: Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci USA 107: 8242-8247, 2010.
5. Delcuve GP, Khan DH and Davie JR: Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets 17: 29-41, 2013.
6. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 9: 139-148, 2008.
7. Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C, Kalavar M, He Z, Burton J and Lichter S: Histone deacetylase in chronic lymphocytic leukemia. Oncology 81: 325-329, 2011.
8. Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li H, Zhou L, Han YN, Wu KC, Nie YZ, et al: MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1. Oncogene 33: 783-793, 2014.
9. Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789, 2010.
10. Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199, 2010.
11. Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F and Skawran B: Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143: 811-20.e1, 15, 2012.
12. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, Ooi LL and Lee CG: MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J 26: 3032-3041, 2012.
13. Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, et al: Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 27: 871-878, 2013.
14. Chakraborty S, Mazumdar M, Mukherjee S, Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A and Das T: Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett 588: 549-559, 2014.
15. LeBoeuf M, Terrell A, Trivedi S, Sinha S, Epstein JA, Olson EN, Morrisey EE and Millar SE: Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev Cell 19: 807-818, 2010.
16. Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong X, Tan G, Wei Z, et al: Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 13: 1589-1598, 2014.
17. Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, et al: Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell Signal 26: 1030-1039, 2014.
18. Wei Z, Jiang X, Liu F, Qiao H, Zhou B, Zhai B, Zhang L, Zhang X, Han L, Jiang H, et al: Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo. Tumour Biol 34: 181-192, 2013.
19. Naor D, Nedvetzki S, Golan I, Melnik L and Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci 39: 527-579, 2002.
20. Scott GK, Mattie MD, Berger CE, Benz SC and Benz CC: Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66: 1277-1281, 2006.
21. Izzotti A, Cartiglia C, Steele VE and De Flora S: MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res 751: 287-303, 2012.
22. CIP1/WAF1. Mol Ther 21: 1678-1686, 2013.
23. Nalls D, Tang SN, Rodova M, Srivastava RK and Shankar S: Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6: e24099, 2011.
24. Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, Nomura Y, Yoshida M, Hayashi T, Oishi N, et al: The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 60: 127-134, 2014.
25. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215, 2011.
26. Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen Q, Leng W, Chen L, Tang Q and Bi F: CD44 acts through RhoA to regulate YAP signaling. Cell Signal 26: 2504-2513, 2014.
27. Zöller M: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11: 254-267, 2011.
28. Sumoza-Toledo A and Santos-Argumedo L: The spreading of B lymphocytes induced by CD44 cross-linking requires actin, tubulin, and vimentin rearrangements. J Leukoc Biol 75: 233-239, 2004.
29. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM and Kuo ML: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120: 2600-2608, 2007.
30. McConnell BV, Koto K and Gutierrez-Hartmann A: Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer 10: 75, 2011.
31. Murphy G and Nagase H: Progress in matrix metalloproteinase research. Mol Aspects Med 29: 290-308, 2008.
32. Hanna S and El-Sibai M: Signaling networks of Rho GTPases in cell motility. Cell Signal 25: 1955-1961, 2013.
33. Struckhoff AP, Rana MK and Worthylake RA: RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci 16: 1915-1926, 2011.
34. Kim Y, Lee YS, Choe J, Lee H, Kim YM and Jeoung D: CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283: 22513-22528, 2008.